Brentuximab vedotin is currently approved for CHL, anaplastic large cell lymphoma (ALCL) (another lymphoma where malignant cells uniformly express CD30), as well as CD30-expressing peripheral T-cell lymphomas and mycosis fungoides (MF) [ADCETRIS prescribing information]. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.